SUMMIT Trial: Tirzepatide Reduces Heart Failure Risk in Obese Patients With HFpEF

SUMMIT: Tirzepatide Enters the Heart Failure Arena

Heart failure with preserved ejection fraction (HFpEF) is one of cardiology's most challenging conditions. Accounting for roughly half of all heart failure cases, HFpEF has historically had no effective pharmacological treatments — until the obesity-heart failure connection revealed a new therapeutic target. The SUMMIT trial, presented at the American Heart Association (AHA) Scientific Sessions in November 2024, demonstrated that tirzepatide could significantly reduce heart failure events in obese patients with HFpEF [1].

Understanding HFpEF and Obesity

HFpEF is a form of heart failure where the heart pumps normally (preserved ejection fraction ≥50%) but fills abnormally, leading to fluid retention, exercise intolerance, and progressive disability.

The Obesity Connection:

• Over 80% of HFpEF patients are overweight or obese
• Excess adipose tissue increases blood volume, cardiac workload, and systemic inflammation
• Visceral fat produces inflammatory cytokines that directly damage the heart
• Obesity-related HFpEF is increasingly recognized as a distinct phenotype

This connection made tirzepatide — with its dramatic weight loss and anti-inflammatory effects — a logical candidate for HFpEF treatment [2].

Study Design

The SUMMIT trial was a randomized, double-blind, placebo-controlled Phase 3 trial:

• Population: ~700 adults with HFpEF (EF ≥50%) and obesity (BMI ≥30)
• Intervention: Tirzepatide (escalated to maximum tolerated dose, up to 15 mg)
• Comparator: Placebo
• Duration: 52 weeks
• Primary Endpoint: Composite of cardiovascular death or worsening heart failure events (hospitalization or urgent visit for heart failure)

Key Inclusion Criteria:

• NYHA Class II-IV heart failure symptoms
• Elevated natriuretic peptides (NT-proBNP ≥150 pg/mL or BNP ≥50 pg/mL)
• BMI ≥30 kg/m²
• Stable heart failure medications for ≥4 weeks

Primary Outcome Results

Tirzepatide demonstrated a significant reduction in the primary composite endpoint:

• Composite of CV death or worsening HF: ~38% relative risk reduction (HR ~0.62)
• Worsening heart failure events: Significantly reduced
• Cardiovascular death: Numerically lower (trial not powered for individual components)

The Kaplan-Meier curves separated early and continued to diverge throughout the 52-week treatment period, suggesting that the benefit was sustained and potentially increasing over time [1].

Symptom and Functional Improvements

Beyond hard clinical endpoints, tirzepatide produced meaningful improvements in how patients felt and functioned:

Kansas City Cardiomyopathy Questionnaire (KCCQ):

• Tirzepatide produced clinically meaningful improvements in KCCQ scores
• Improvements were seen in both the clinical summary score and overall summary score
• The magnitude of improvement exceeded the minimum clinically important difference

Exercise Capacity:

• 6-minute walk distance improved significantly with tirzepatide
• Patients reported less dyspnea and fatigue with daily activities

NYHA Functional Class:

• A greater proportion of tirzepatide patients improved by at least one NYHA class
• Fewer patients experienced worsening of their functional class [1].

Weight Loss and Metabolic Effects

As expected, tirzepatide produced substantial weight loss:

• Mean weight loss: Approximately 13-15% of body weight
• Waist circumference: Significant reduction
• Systemic inflammation: CRP and other inflammatory markers decreased
• Blood pressure: Modest but clinically relevant reductions
• Fluid retention: Reduced, as evidenced by decreased NT-proBNP levels

The reduction in NT-proBNP is particularly significant — this biomarker reflects cardiac wall stress and is a strong predictor of heart failure outcomes. Its reduction suggests that tirzepatide's benefits extend beyond simple weight loss to direct cardiac unloading [1].

Mechanism of Benefit in HFpEF

The mechanisms by which tirzepatide improves HFpEF likely include:

1. Hemodynamic unloading: Weight loss reduces blood volume, cardiac preload, and afterload
2. Reduced pericardial fat: Epicardial and pericardial fat contribute to cardiac compression in obesity-related HFpEF
3. Anti-inflammatory effects: Reduced systemic and cardiac inflammation
4. Improved endothelial function: Better vascular compliance and reduced arterial stiffness
5. Metabolic improvements: Better insulin sensitivity and reduced lipotoxicity
6. Direct cardiac effects: GLP-1 receptors are present on cardiomyocytes, and GLP-1 agonism may have direct cardioprotective effects

Comparison to Semaglutide in HFpEF

The STEP-HFpEF trial previously showed that semaglutide 2.4 mg improved symptoms and exercise capacity in obese HFpEF patients. SUMMIT builds on this by:

• Demonstrating hard clinical endpoint reduction (CV death + worsening HF), not just symptom improvement
• Using tirzepatide's dual mechanism for potentially greater weight loss and metabolic benefit
• Providing evidence for a new drug class in heart failure treatment

Together, these trials establish that targeting obesity in HFpEF is a viable and effective treatment strategy [3].

Clinical Implications

SUMMIT has profound implications for both cardiology and obesity medicine:

1. New treatment paradigm: First evidence that a weight loss medication can reduce hard heart failure outcomes
2. Expanded indication: Potential FDA approval for tirzepatide in obesity-related HFpEF
3. Cardiology integration: Obesity treatment becomes a core component of heart failure management
4. Phenotype-specific therapy: Validates the concept of treating the obesity phenotype of HFpEF specifically
5. Multidisciplinary care: Strengthens the case for collaboration between cardiologists and obesity medicine specialists

References

1. Packer M, Zile MR, Kramer CM, et al. "Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity." New England Journal of Medicine. 2025. Presented at AHA 2024.

2. Borlaug BA, Jensen MD, Kitzman DW, et al. "Obesity and Heart Failure With Preserved Ejection Fraction: New Insights and Pathophysiological Targets." Cardiovascular Research. 2023;119(13):2224-2237. PubMed: 37161491

3. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity." New England Journal of Medicine. 2023;389(12):1069-1084. PubMed: 37622681